Ionis Pharmaceuticals (IONS) to Release Earnings on Tuesday

Ionis Pharmaceuticals (NASDAQ:IONS) will announce its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($1.07) per share for the quarter. Ionis Pharmaceuticals has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Wednesday, February 21st. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.72. The firm had revenue of $325.00 million for the quarter, compared to analysts’ expectations of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative return on equity of 90.29%. Ionis Pharmaceuticals’s quarterly revenue was up 113.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.37) EPS. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Ionis Pharmaceuticals Stock Down 2.6 %

Ionis Pharmaceuticals stock opened at $41.97 on Friday. The stock has a market cap of $6.12 billion, a price-to-earnings ratio of -16.39 and a beta of 0.41. The company has a current ratio of 5.90, a quick ratio of 5.83 and a debt-to-equity ratio of 3.18. The company’s 50-day moving average price is $43.07 and its two-hundred day moving average price is $46.98. Ionis Pharmaceuticals has a 52 week low of $34.32 and a 52 week high of $54.44.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on IONS shares. Oppenheimer raised their target price on shares of Ionis Pharmaceuticals from $72.00 to $75.00 and gave the company an “outperform” rating in a research note on Tuesday, April 9th. StockNews.com upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 24th. Royal Bank of Canada raised their price objective on shares of Ionis Pharmaceuticals from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Friday, January 26th. JPMorgan Chase & Co. raised their price objective on shares of Ionis Pharmaceuticals from $52.00 to $55.00 and gave the company a “neutral” rating in a research report on Thursday, February 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $57.67.

Insider Activity

In other news, EVP Joseph Baroldi sold 4,006 shares of the business’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total value of $166,649.60. Following the sale, the executive vice president now owns 19,631 shares in the company, valued at approximately $816,649.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.65% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.